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Hematopoietic stem and progenitor cells (HSPCs)
are exposed to low levels of oxygen in the bone
marrow niche, and hypoxia-inducible factors (HIFs)
are the main regulators of cellular responses to
oxygen variation. Recent studies using conditional
knockout mouse models have unveiled a major role
for HIF-1a in the maintenance of murine HSCs; how-
ever, the role of HIF-2a is still unclear. Here, we show
that knockdown of HIF-2a, and to a much lesser
extent HIF-1a, impedes the long-term repopulating
ability of human CD34+ umbilical cord blood cells.
HIF-2a-deficient HSPCs display increased produc-
tion of reactive oxygen species (ROS), which subse-
quently stimulates endoplasmic reticulum (ER)
stress and triggers apoptosis by activation of the
unfolded-protein-response (UPR) pathway. HIF-2a
deregulation also significantly decreased engraft-
ment ability of human acute myeloid leukemia
(AML) cells. Overall, our data demonstrate a key
role for HIF-2a in the maintenance of human HSPCs
and in the survival of primary AML cells.
INTRODUCTION
Multipotent hematopoietic stem cells (HSCs) reside in niches
within the bone marrow (BM) and have a unique capacity to sus-
tain life-long multilineage hematopoiesis (Li and Xie, 2005; Mor-
rison and Spradling, 2008; Orkin and Zon, 2008; Scadden, 2006).
It has been suggested that mammalian BM is relatively hypoxic
compared to other tissues, with recent evidence suggesting
that more primitive HSCs are localized in the most hypoxic
microenvironment of the BM (Giuntoli et al., 2007; KubotaCellet al., 2008; Le´vesque et al., 2007; Parmar et al., 2007). Within
the stem cell niche, HSCs are maintained in a quiescent state
with a low level of oxidative stress, which helps to prevent their
differentiation and exhaustion (Jang and Sharkis, 2007).
The hypoxia-inducible factors (HIFs) are the main transcrip-
tional factors responding to oxygen variation (Semenza,
2009a). HIF-1 and HIF-2 are heterodimeric proteins belonging
to the basic helix-loop-helix. Regulation of HIF activity is medi-
ated primarily through the stability of the alpha subunit. In nor-
moxia, hydroxylation of the HIF-a protein leads to a decrease
in the stability of HIF-a through rapid ubiquitination by the E3
ubiquitin ligase von Hippel-Lindau tumor suppressor protein
(VHL) and degradation by the 26S proteosome. Under hypoxic
conditions, HIF-a proteins are elevated as a result of reduced
hydroxylation. The stabilized HIF-a subunit dimerizes with the
HIF-1b subunit and activates the transcription of target genes
involved in glucose metabolism, erythropoiesis, iron homeosta-
sis, angiogenesis, and cell survival (Semenza, 2009a).
Additionally, under normoxic conditions, several factors such
as thrombopoietin (TPO) and stem cell factor (SCF) have been
shown to stabilize HIF-a subunits in hematopoietic cells (Kirito
et al., 2005; Pedersen et al., 2008), suggesting an additional
role for HIFs beyond that of responding to oxygen variations in
the microenvironment.
In mice, the deletion of Hif-1a (Ryan et al., 1998) and Hif-1b
(Adelman et al., 1999) results in embryonic lethality at E10.5,
whereas the embryonic or perinatal lethality resulting from dele-
tion of Hif-2a depends on the mouse microenvironment (Scorte-
gagna et al., 2003a, 2003b). Recently, detailed analyses of the
role of Hif-1a in adult mouse HSCs have been performed (Sim-
sek et al., 2010; Takubo et al., 2010), demonstrating that the
regulation of Hif-1a levels is critical for HSC maintenance in the
hypoxic BM niche. Indeed, in Hif-1a -deficient mice, HSCs are
less quiescent and their numbers decrease when exposed to
various stressors (including BM transplantation, myelo-suppres-
sion, and aging) in a p16Ink4a/p19Arf-dependent manner. Further
to this, the overstabilization of Hif-1a through biallelic loss of VhlStem Cell 13, 549–563, November 7, 2013 ª2013 Elsevier Inc. 549
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shows an impairment in their repopulating capacity, an effect
similar to that observed in conditional knockouts of cited2, a
competitor of Hif-1a for CBP/p300 (Kranc et al., 2009). Interest-
ingly, monoallelic loss of Vhl also induces cell cycle quiescence
yet improves BM engraftment after transplantation, suggesting
that the regulation of the Hif-1a level is essential for mouse
HSCs. Transcriptional activation of Hif-1a by Meis1 is reported
to be involved in the anaerobic phenotype that characterizes
HSCs in hypoxia (Simsek et al., 2010). Also, Miharada et al.
have proposed a model by which Hif-1a induces Cripto/
GRP78 signaling in the hypoxic HSC niche, which itself regulates
the quiescence of HSCs by inducing a high level of glycolytic
activity (Miharada et al., 2011). Overall, these studies have iden-
tified Hif-1a as a major regulator of mouse HSCs. With respect
to Hif-2a, so far it has been shown to regulate Epo expression
in the adult mouse (Gruber et al., 2007), contribute to tumor
aggressiveness (Qing and Simon, 2009), and maintain the undif-
ferentiated state of human neural crest-like neuroblastoma
tumor-initiating cells (Pietras et al., 2009) and glioma-initiating
stem cells (Li et al., 2009). Hif-2a/ mice have also been
reported to suffer multiple-organ pathology, including pancyto-
penia in the BM. Most importantly, Scortegagna et al. have sug-
gested a central rheostat role for Hif-2a in both the maintenance
of ROS levels and mitochondrial homeostasis (Scortegagna
et al., 2003a, 2003b).
In contrast to the extensive work done in mice, at present what
is known about the role of hypoxia and HIF-a in human HSC
regulation remains limited. It has been reported that HIF-1a is ex-
pressed in LineageCD34+CD38 cells from BM (Danet et al.,
2003), as well as in circulating CD34+ and CD133+ cells under
normoxic conditions (Piccoli et al., 2007). Furthermore, hypoxic
ex vivo culture of BMcells or primitive hematopoietic progenitors
has been shown to result in better maintenance of a primitive
phenotype (Danet et al., 2003) and cell cycle quiescence (Her-
mitte et al., 2006). Mutations in VHL, PHD, or HIF-2a have
been reported to lead to polycythemia in Chuvash’s disease
(Semenza, 2009b) through an increase in EPO production by
the kidney and an increased sensitivity to EPO in these patients
(Ang et al., 2002; Hickey et al., 2007).
HIF proteins have been also shown to be involved in cancer
development, where high expression of HIF-a correlates with
poor patient prognosis (Keith et al., 2012). A recent report sug-
gests that HIF-1a is required for human leukemic stem cell
(LSC) function in AML (Wang et al., 2011). However, the role of
HIF-2a protein in human AML remains largely unknown.
In this work, we examine the effect of the knockdown (KD) of
HIF-1a and HIF-2a in human HSPCs. We observe that silencing
HIF-2a, and to a lesser degree HIF-1a, impedes the repopulat-
ing capacity of CD34+-derived umbilical cord blood (UCB) cells
in vivo. We demonstrate that HIF-2a KD HSPCs show signs of
endoplasmic reticulum (ER) stress and activate the unfolded
protein response (UPR) pathway, which ultimately affects the
survival of the HSPCs. Moreover, we observe that the increase
in the ER stress response in HIF-2a KD cells is due to an in-
crease in reactive oxygen species (ROS) production. We also
describe that cells from AML patient samples are dependent
on the level of HIF-2a for their survival. Collectively, the data
in our report provide further evidence of a central role for550 Cell Stem Cell 13, 549–563, November 7, 2013 ª2013 Elsevier InHIF-2a in protecting HSPCs and AML cells from apoptosis
induced by ER stress.
RESULTS
The Expression of HIF-a Subunits in Human CD34+Cells
and Their Efficient KD Using shRNA Lentiviral Vectors
It has previously been shown that HIF-1a is expressed in
LinCD34+CD38 cells derived from the BM (Danet et al.,
2003) and is present on peripheral blood cells (Piccoli et al.,
2007). We first confirmed the expression of HIF-1a in freshly iso-
lated CD34+ CB-derived cells and additionally demonstrated the
expression of HIF-2a in these cells (Figure 1A). As expected, we
were able to see an increase in HIF-1a and HIF-2a after incu-
bating CD34+ cells with cobalt chloride (CoCl2), which prevents
the prolyl-hydroxylase activity leading to HIF degradation (Fig-
ure 1A) (Figure S1A available online).
To investigate the role of each of the HIF-a subunits in human
HSPCs, we constructed bicistronic lentiviral vectors carrying two
distinct promoters, EF1a and H1, driving green fluorescent pro-
tein (GFP) (reporter) and a small hairpin RNA (shRNA) against the
HIF-1a (sequence published in Rezvani et al., 2007) or HIF-2a
subunit, respectively (Figure S1B). To confirm the specificity
and efficiency of these vectors, CD34+ cells were transduced
(45%–80% transduction efficiency), FACS-sorted 4 days post-
transduction, and cultured for an additional 4 days prior to our
assessment of mRNA levels. A significant reduction in mRNA
levels was observed for both HIF-1a and HIF-2a vectors relative
to controls, with a decrease of 88% and 78%, respectively (Fig-
ure 1B). The KD was also confirmed at the protein level in CD34+
cells (Figure 1C) and in 293T cells (Figure S1C). The shHIF1a
used in this study has been previously validated elsewhere
(Rezvani et al., 2007). However, to confirm the specificity and
exclude off-target effects of the shRNA for HIF-2a, we tested a
second shHIF2a (shHIF2a.2) (Figure S1D). Using this second
vector, we confirmed an efficient KD at the protein level, as
well as similar defects in vivo compared to the first shRNA
used (shHIF2a.1) (Figure S1E). We then used the construct that
gave us the best silencing activity (shHIF2a.1) for the rest of
this study.
To further confirm the specificity of our shRNA vectors, we
looked at the effect of the KD on known target genes of HIF-1a
(VEGFA and LDHA) and HIF-2a (VEGFA and HES-1). We
observed a significant reduction of VEGFA expression after
bothHIF-1a andHIF-2a silencing, a reduction of LDHA following
HIF-1aKD, and a reduction ofHES-1 after HIF-2aKD (Figure 1D),
indicating that our shRNA vectors were specific.
SilencingHIF-2a and, to a Lesser Extent,HIF-1a, Affects
Human Short-Term Repopulating Cells
It has been reported that the formation of myelo-erythroid pro-
genitors from embryonic or yolk sac cells derived from Hif-1a-,
Hif-2a-, and Hif-1b-knockout mice is impaired (Adelman et al.,
1999; Covello et al., 2006; Yoon et al., 2006). However, no major
impediment to the in vitro functions of adult mouse HSCs has
been observed using a conditional knockout model of Hif-1a
(Takubo et al., 2010). We therefore examined the effect of
HIF-a KD in human hematopoietic progenitor cells. The number
of myeloid colonies generated from GFP+ cells was equivalent inc.
Figure 1. Expression of HIFa Subunits in Human CD34+ Cells and Their Efficient KD Using shRNA Lentivirus Vectors
(A) HIF-1a and HIF-2a protein expression in freshly purified CD34+ cells cultured for 6 hr in the presence or absence of CoCl2.
(B) RT-QPCR for HIF-1a (left) and HIF-2a (right) expression in CD34+ cells. CD34+ cells were transduced with shCtl, shHIF1a, and shHIF2a, and sorted on
day 4 posttransduction based on GFP+. Gene expression was normalized to B-ACTIN gene and then to the shCtl (n = 3). Results are shown as the mean ± SEM.
*p < 0.05.
(C) HIF-1a (upper) and HIF-2a (lower) protein expression in CD34+ cells after transduction. CD34+ cells were transduced with shCtl, shHIF1a, and shHIF2a, and
sorted on day 4 posttransduction based on GFP+ cells and cultured for another 6 hr in the presence of CoCl2 before protein extraction and western blot analysis.
(D) RT-QPCR for VEGFA (common target gene for HIF-1a and HIF-2a), LDHA (HIF-1a target gene), and HES-1 (HIF-2a target genes) expression in CD34+
transduced cells cultured at 20% and 3% of oxygen. RT-PCR was normalized to B-ACTIN and data are expressed relative to shCtl at 3% oxygen (n = 3–5).
Results are shown as the mean ± SEM. *p < 0.05.
See also Figure S1.
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onies was significantly diminished upon HIF-2a KD, where there
was a 61% reduction compared to the control. No effect was
observed in HIF-1a silenced cells (Figure 2A). Further analysis
of the effect of HIF-2a KD on erythropoiesis is being investigated
(data not shown).
To determine whether HIF-a KD has an effect on the prolifera-
tion of CD34+ cells, we performed a short-term liquid culture
assay in the presence of growth factors. Under these conditions,
we showed that silencing HIF-2a significantly reduced the prolif-
eration of CD34+ cells (Figure 2B); however, no change was seen
when HIF-1a was silenced. This effect on proliferation was notCelldue to an increase in apoptosis (Figure 2C). Thus, under nor-
moxic conditions, only the downregulation of HIF-2a had an
effect on CD34+ cells, reducing both erythroid colony formation
and proliferation.
We further examined the effect of HIF-a silencing in vivo using
the NOD-SCID/IL2Rgnull (NSG) xenotransplantation model, as
depicted in Figure 2D (left panel). Immediately after transduction,
cells were injected intravenously into mice and human graft was
examined 6 weeks posttransplantation. The percentage of GFP+
cells within the human CD45+ fraction was determined by flow
cytometry. A loss of transduced cells was observed in both
HIF-1a and HIF-2a KD conditions, although this effect was lessStem Cell 13, 549–563, November 7, 2013 ª2013 Elsevier Inc. 551
Figure 2. HIF-1a and HIF-2a KDs Differently Affect Human Progenitor Compartment
(A) Colony forming unit (CFU) assay of CD34+ cells transduced with shCtl, shHIF1a, or shHIF2a. Five hundred CD34+ GFP+ transduced cells were plated. Two
weeks later the number of colonies was determined (n = 3).
(B) CD34+ transduced and sorted cells were grown in expansion medium and the number of cells was determined every 2–3 days. The growth curve represents
cumulative cell numbers (n = 3).
(C) Early apoptosis was assessed on transduced CD34+ cells after 6 days in liquid culture. Data represents the percentage of Annexin V+ cells in the DAPI
population (n = 3).
(D) Left panel, schematic of the in vivo short-term repopulation assay. CD34+ cells were transduced with shCtl, shHIF1a, and shHIF2a and then injected into NSG
mice. Human graft was determined 6 weeks posttransplantation. Right panel, percentage of GFP+ cells in the human engraftment. Results are shown as
normalized to 100% GFP+ at day 4. Results represent three to six independent experiments and each dot represents one mouse.
(E) Left panel, schematic of the homing assay. CD34+ cells were transduced with shCtl, shHIF1a, and shHIF2a and then injected into mice. Human graft was
determined 24 hr after transplantation. Right panel, percentage of GFP+ cells. Results are shown as normalized to 100% GFP at day 4. Graph represents two
independent experiments (n = 6 mice per bar).
Results in (A), (B), and (D) are shown as mean ± SEM. *p < 0.05.
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value at day 4) than that in HIF-2a KD (up to 70%; see Figure 2D,
right panel).
Hypoxia and HIFs have been described as important factors
driving the expression of the chemokine SDF-1a (Ceradini
et al., 2004) and its receptor, CXCR4, in tumors (Liu et al.,
2006). Based on the role of SDF-1a and CXCR4 in human stem
cell homing and repopulation (Lapidot and Kollet, 2002), we hy-
pothesized that the KD of both HIF-a subunits might affect the
homing of transduced cells. To test this hypothesis, we trans-
duced CD34+ cells and kept these cells in liquid culture for
4 days prior to injection into mice (see schematic protocol, Fig-
ure 2E, left panel). Mice were sacrificed 24 hr after injection
and human hematopoietic cell homing was determined by the
percentage of GFP-expressing cells among human cells (Fig-
ure 2E, right panel). The percentage of GFP-expressing cells
within human grafts was not significantly different between the
three groups (shCtl, shHIF1a, and shHIF2a), suggesting that
there is no homing defect that occurs upon the silencing of the
HIF-a subunits.
HIF-2a KD Impairs the Long-Term Reconstitution Ability
of Human HSPCs
Using a conditional knockout mouse model, it was recently
shown thatHif-1a is required to sustain long-term hematopoietic
repopulation capacity under stress conditions (Takubo et al.,
2010), whereas Hif-2a knockout only causes a minor effect in
the primitive hematopoietic compartment (Scortegagna et al.,
2003a). To investigate the role of HIF-a in the long-term mainte-
nance of human HSPCs, we followed the percentage of GFP+
cells in transplanted NSG mice over time by BM aspiration sam-
pling at 3, 6, 12, and 24weeks (at the time of sacrifice) after trans-
plantation, as described in Figure 3A. A progressive decrease in
the percentage of GFP+ cells in the first 12 weeks was observed
in mice transplanted with shHIF1a-transduced cells as com-
pared to the control condition (shCtl) (Figure 3B), an effect that
plateaued after 12 weeks. A more dramatic drop in the first
12 weeks was observed upon transplantation of shHIF2a-trans-
duced cells (Figure 3B), which persisted until 24 weeks. A similar
decrease in the myeloid (CD33+) and lymphoid (CD19+) com-
partments was observed in both shHIF1a and shHIF2a cells
(Figure 3C), suggesting that in both cases, silencing affected
immature HSPCs. To demonstrate that the decrease was not
due to a change in the distribution of the cells in the different
hematopoietic tissues, we checked the engraftment of trans-
duced cells in the BM, peripheral blood (PB), and spleen of these
mice (Figure 3D). We observed the same decrease in engraft-
ment in each of the different tissues, affecting both myeloid
and lymphoid compartments (Figure 3E).
Because HIF-2a KD cells showed a significant decrease in
reconstitution 3 weeks after injection, we wondered whether
this might be due to a defect in the retention and/or anchorage
of the cells in their niche. To assess this question we examined
the effect of HIF-2a silencing on engrafted cells 1 and 2 weeks
after transplantation. One week posttransplantation, we did not
observed any loss of transduced cells in the HIF-2a KD as
compared to controls. However, 1 week later, a mild but signifi-
cant reduction in engraftment was detected (Figure S2A). These
results suggest that HIF-2a does not play a major role in theCellretention of the HSCs in their niches. We confirmed this by
tracking HSCs in their niches using noninvasive intravital micro-
scopy of the calvaria. For this purpose, CD34+CD38 HSPCs
were transduced and sorted 4 days later based on GFP expres-
sion. Cells were then stainedwith CFSE and injected intomice as
schematically depicted (Figure S2B, left panel). Based on un-
published data from our group, we have observed that after
4 days posttransplantation, HSCs have reached their niches
(K. Foster, F. Lassailly, F. Anjos-Afonso, E. Currie, and D.B.,
data not shown). At this stage, we can thusmeasure the distance
of each HSPC to the closest endothelial cells or endosteal re-
gion. Using these measurements, we did not observe any differ-
ence in the positioning of HSPCs between control andHIF-2aKD
(Figure S2B, right panel). These results confirmed that HIF-2a
silencing has no effect on the HSC lodgement/retention in their
niches in the first week posttransplant.
To evaluate the effect on the most primitive compartment, we
compared the percentage of CD34+CD38 cells present in the
BM of thesemice 24weeks posttransplant. We observed a slight
but significant decrease in the CD34+CD38+ HPC fraction and a
nonsignificant decrease in the CD34+CD38 HSPC compart-
ment in shHIF1a transplanted mice. This was in contrast to a
90% reduction in both subfractions in the shHIF2a-silenced
group, suggesting a key role for HIF-2a in the human HSPC
compartment (Figure 3F).
To address the impact that each of the HIF-a subunits could
have on the self-renewal capacity of human HSPCs, we went
on to perform secondary transplantations. Mice were injected
with a pool of BM cells from the primary grafts and sacrificed
24 weeks posttransplant. Based on the low percentage of
GFP+ cells retrieved from the shHIF2a group, we were only
able to inject 6 mice, as compared to 16 mice in the shHIF1a
group. Nevertheless, a further 48% reduction in the percentage
of shHIF-2a transduced cells was observed at 24 weeks
postsecondary transplantation as compared to the level ob-
tained at 24 weeks postprimary transplantation; once again,
in contrast, no further reduction was observed with shHIF1a
cells (Figure 3G). This data strongly demonstrates that
the maintenance of human long-term repopulating cells with
self-renewing ability is dependent on HIF-2a. Recently, Koca-
bas et al. described that Hif-1a/ long-term HSCs show a
compensatory upregulation of Hif-2a mRNA (Kocabas et al.,
2012). Similarly, we have observed that the KD of HIF-1a in
human CD34+ cells cultured for 4 days under hypoxia
(3% O2) or normoxia (20% O2) (data not shown) results in a
3-fold increase in HIF-2a mRNA levels (Figure S2C). This was
further confirmed by the increase in expression of HES-1, a
downstream target of HIF-2a (Figure 1D). This marked compen-
satory upregulation of HIF-2a in shHIF1a-transduced cells
could explain why no significant long-term effect was observed
on shHIF1a HSPCs.
The HIF pathway is a well-established regulator of the cell
cycle. In order to determine if the dramatic effect that
HIF-2a silencing had on HSPCs was due to a defect in pro-
liferation, we performed cell cycle analysis on engrafted cells
1 and 2 weeks after injection. No differences in any phases of
the cell cycle were observed in the absence of HIF-2a, sug-
gesting that the effect observed is independent of cell cycle
(Figure S2D).Stem Cell 13, 549–563, November 7, 2013 ª2013 Elsevier Inc. 553
Figure 3. HIF-2a Is Essential for the Long-Term Engraftment Ability of the Human Hematopoietic Cells in NSG Mice
(A) Schematic representation of the in vivo primary and secondary transplantation assay and BM sampling at different time points. Results represent three to six
independent experiments and total number of mice are as follows: shCtl, n = 14; shHIF-1a, n = 19; shHIF-2a, n = 12.
(B) In vivo kinetic of transduced cells in human hematopoietic population. Percentages of GFP+ cells in total human CD45+ cells at the indicated time are shown.
Results are shown as normalized to 100% GFP at day 4 as mean ± SD. *p < 0.05.
(C) In vivo kinetic of transduced myeloid and lymphoid population. Percentages of GFP+ cells in total CD33+ (left panel) and in total CD19+ cells (right panel) at the
indicated time are shown. Results are shown as normalized to 100% GFP at day 4 as mean ± SD. *p < 0.05.
(D and E) Twenty-four weeks after transplantation mice were sacrificed and the percentage of GFP+ cells in bone marrow (BM), spleen, and peripheral blood (PB)
was analyzed. (D) GFP+ cells in total CD45+ human cells. (E) Left panel, as in (D), but in total CD45+CD33+-myeloid cells; right panel, as in (D), but in total
CD45+CD19+-B-lymphoid cells. Results are shown as mean ± SD. *p < 0.05.
(F) Twenty-four weeks after the first transplantation, mice were sacrificed and the percentage of GFP+ cells in CD34+CD38lo/ and CD34+CD38+ populations was
analyzed by FACS. Results are shown as mean ± SEM. *p < 0.05.
(G) BM from primary animals was injected into secondary mice. Twenty-four weeks later, percentages of GFP+ cells within the human graft were analyzed by
FACS. Results are shown as normalized to 100% GFP at week 24 as mean ± SEM. Each dot represents a mouse.
See also Figure S2.
Cell Stem Cell
Role of HIF-2a in Human HSPCs and AML
554 Cell Stem Cell 13, 549–563, November 7, 2013 ª2013 Elsevier Inc.
Figure 4. HIF-1b KD in CD34+ Cells Recapit-
ulates HIF-2a KD Phenotype
(A) Left panel, RT-QPCR for HIF-1b expression in
CD34+ cells transduced with shCtl or shHIF1b
(n = 3). Right panel, HIF-1b protein expression in
CD34+ cells transduced with shCtl or shHIF1b and
cultured for 6 hr in presence of CoCl2.
(B) RT-QPCR for VEGFA expression in CD34+
transduced cells cultured at 20% and 3% of
oxygen. B-ACTIN was used as a housekeeping
gene (n = 3).
(C) CFU assay of CD34+ cells transduced with shCtl
and shHIF1b. Five hundred GFP+ CD34+ were
plated and 2 weeks later numbers of colonies were
determined (n = 3).
(D) CD34+ transduced cells were grown in expan-
sion medium and the number of cells was deter-
mined every 2–3 days. The growth curve represents
cumulative cell numbers (n = 3).
(E) Early apoptosis was assessed on CD34+
transduced cells after 6 days in liquid culture. Data
represents the percentage of Annexin V+ cells in the
DAPI population (n = 3).
(F) Mice were transplanted with CD34+ cells
transduced with either shCtl or shHIF1b. Six weeks
(left panel) or twelve weeks (right panel) after
transplantation mice were killed and the percent-
age of GFP+ cells in the human engraftment was
analyzed. Results are shown as normalized to
100% GFP at day 4. Results represent two inde-
pendent experiments and each dot represents one
mouse.
Results are shown as mean ± SEM. *p < 0.05.
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To better understand the role of HIF-a in HSPCs, we decided to
knock down the binding partner of the HIF-a subunits, the
constitutively expressed b subunit (HIF-1b). We confirmed the
downregulation of HIF-1b using an shHIF1b at both mRNA and
protein level (Figure 4A, left and right panels), and by noting
the decrease in the downstream target gene VEGFA (Figure 4B).
We examined the effect of the downregulation of HIF-1b
on progenitor formation, cell proliferation, and apoptosis. We
observed a specific decrease in erythroid progenitors (Figure 4C)
and cell proliferation (Figure 4D) without a change in the level of
apoptosis (Figure 4E). These results closely overlap with the
effects seen in HIF-2a KD. The similarity in the effect of HIF-1b
and HIF-2a KD in HSPCs was further confirmed in vivo, at both
6 (Figure 4F, left panel) and 12 weeks (Figure 4F, right panel)
posttransplant, where a significant decrease in engraftment
was seen at both time points, confirming the role of HIF com-
plexes in the maintenance of human HSPCs.
HIF-2a KD Increases ROS Production and Affects
Mitochondrial Homeostasis
Because our results suggested that HIF-2a plays an important
role in the maintenance of human long-term self-renewing repo-
pulating stem cells, we decided to focus our efforts on under-
standing the molecular mechanisms by which HIF-2a regulatesCellHSPC biology. To investigate this, human CD34+ cells trans-
duced with shHIF2a were recovered from mouse BM 6 weeks
posttransplantation and subjected to a large-scale gene expres-
sion analysis after we first confirmed the efficiency of HIF-2a
silencing at this time point (61% silencing efficiency at the
mRNA level; Figure S3A). Compared to shCtl-transduced cells,
gene pathway enrichment analysis identified the oxidative
stress, ER stress response, and apoptosis pathways as those
with the largest change in gene signature (Figure 5A, left panel).
Based on the gene expression signature for the oxidative
stress pathway observed in shHIF2a cells, and the known role
of HIF-2a in regulating reactive oxygen levels (Scortegagna
et al., 2003a, 2003b), we examined the level of ROS present in
these cells both in vitro and at 6 weeks posttransplantation. As
hypothesized, ROS levels were significantly increased in liquid
culture (Figure S3B) and in all compartments (CD34+CD38,
Lin+ cells and a trend in CD34+CD38+ cells) in vivo after trans-
duction with shHIF2a as compared to shCtl (Figure 5B).
Mitochondria are a major source of ROS and mechanisms to
prevent elevated ROS during oxidative phosphorylation require
the activity of antioxidant enzymes. Recently, it was shown
that HIF-2a regulates the expression of genes encoding antiox-
idant enzymes in mice (Bertout et al., 2009; Gordan et al., 2007).
Based on the increase in ROS, we examined the level of expres-
sion of antioxidant genes, such as superoxide dismutase 2
(SOD2), as well as genes involved in mitochondria homeostasis,Stem Cell 13, 549–563, November 7, 2013 ª2013 Elsevier Inc. 555
Figure 5. HIF-2a KD In Vivo Increases ROS Production and Affects Mitochondria Homeostasis
(A) Large-scale gene expression on human CD34+ GFP+ cells sorted from mice at 6 weeks. Gene pathway enrichment analysis ranked on top position the
oxidative phosphorylation pathway, ER stress response, and apoptosis and survival. A heat-map is presented below for two different mice in each condition
(shCtl and shHIF-2a).
(B) In vivo quantification of ROS in shCtl and shHIF2a in LinCD34+CD38lo/, LinCD34+CD38+, and Lin+ cells 6 weeks posttransplantation. Data is presented as
percentage of ROS increase in shHIF2a compared to the shCtl (normalized to 100%). ShCtl, n = 5 mice; shHIF2a, n = 11 mice. Results are shown as the mean ±
SEM. *p < 0.05.
(C) RT-QPCR for SOD2 (left) and FXN (right) expression in CD34+ cells transduced with shCtl or shHIF-2a. Transduced cells were sorted for GFP+ on day four and
cultured for an extra 7 days under 3% of oxygen. B-ACTIN was used as control (n = 3). The results are expressed in comparison to the level in shCtl. Results are
shown as the mean ± SEM. *p < 0.05.
(D) Mean fluorescence intensity (MFI) of MitoTracker-stained CD34+ cells transduced with shCtl or shHIF2a. (n = 3). Results are shown asmean ± SEM. *p < 0.05.
See also Figure S3.
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observed in shHIF2a transduced CD34+ cells compared to
shCtl (Figure 5C). We also looked at the alterations in mitochon-
drial membrane potential and oxidant stress by performing
MitoTracker staining. We observed a significant decrease in
the mean fluorescence intensity of MitoTracker-stained CD34+
cells transduced with shHIF2a compared to control cells. Taken
together, these data suggest that HIF-2a KD increases ROS pro-
duction and affects mitochondria homeostasis (Figure 5D).
Silencing HIF-2a Increases the ER Stress Induced
by ROS
As mentioned above, our large-scale gene expression analysis
also identified the apoptosis-ER stress response pathway as
one of the top ranked pathways differentially expressed in
shHIF2a transduced CD34+ cells compared to shCtl. Upon ER
stress, UPR is activated through three distinct signaling path-
ways that regulate the expression of genes responsible for
the maintenance of cellular homeostasis: the protein kinase R556 Cell Stem Cell 13, 549–563, November 7, 2013 ª2013 Elsevier In(PKR)-like ER kinase (PERK), the activating transcription factor
6 (ATF6), and the inositol-requiring protein 1a (IRE1a) signaling
transducer pathways (Figure 6A). If ER stress persists and
homeostasis is not restored, UPR signaling induces apoptosis
(Walter and Ron, 2011). Interestingly, factors such as oxidative
stress can induce ER stress (Malhotra and Kaufman, 2007).
To confirm the involvement of the ER stress response and the
induction of the UPR pathway in HIF-2a KD HSPCs, we exam-
ined the expression levels of two ER chaperones, HSPA5 (also
known as 78 kDa glucose regulated protein, GRP78) and
94 KDa glucose regulated protein (GRP94). These genes have
been widely used as sentinel markers of ER stress and UPR
pathway activation. Human transduced GFP+CD34+ cells were
sorted at day 4 posttransduction and cultured for an additional
day before RNA was extracted and RT-PCR was performed.
Upon HIF-2a KD, we observed an increase in both HSPA5 and
GRP94 as compared to control (Figure 6B). We also observed
a mild increase in C/EBP homologous protein (CHOP), a tar-
get gene of the PERK pathway that is expressed under ERc.
Cell Stem Cell
Role of HIF-2a in Human HSPCs and AMLstress-induced cell apoptosis (Figure 6B). To further confirm the
initiation of the UPR pathway by ER stress, we treated our cells
with tunicamycin (TM), a well-known inducer of the UPR
pathway. After their treatment with TM,we observed a significant
increase in HSPA5, growth arrest and DNA damage inducible 34
gene (GADD34), and CHOP, which are key players of the PERK
branch of the UPR pathway, in shHIF2a cells compared to the
shCtl (Figure 6C, left panel). We also observed that the treatment
with TM increased the percentage of apoptotic cells in shHIF2a
cells compared to shCtl (Figure 6C, right panel). Taken together,
these data suggest that HIF-2a-silenced HSPCs have signifi-
cantly increased levels of ER stress and are more susceptible
to apoptosis as a result. We further confirmed the activation of
the PERK signaling pathway in these cells by looking at the
eIF2a phosphorylation. Indeed P-eIF2a was higher in the
HIF-2a KD cells compared to the control while the total eIF2a
protein level remained the same (Figure 6D, left panel, and Fig-
ure S4A). We also assessed the activation status of the other
two branches of the UPR pathway. No activation of the ATF6
branch was observed in HIF-2a KD cells as evidenced by the
low or nondetectable expression of the activated, nuclear form
of ATF6 (ATF650) in both shCtl and shHIF2a cells (Figure S4B).
Additionally, we checked the activation of the IRE-1 pathway
by measuring the mRNA splicing of the XBP-1 transcription
factor, which is a substrate of the IRE-1 activated form. We
observed similar expression levels of the spliced XBP1 mRNA
in both control and HIF-2a KD cells (Figure S4C), suggesting
that this branch is constitutively activated regardless of HIF-2a
levels. These data suggest that HIF-2a silencing in HSPCs trig-
gers ER stress mainly through the activation of the PERK branch
of the UPR signaling cascade.
Finally, we confirmed the activation of the pathway in cells
retrieved from mice 6 weeks posttransplant. We observed an
upregulation of the downstream targets of p-eIF2a, such as
HSPA5, CHOP, and GADD34 (the latter two activated in
response to prolonged ER stress), and a downregulation of
BCL-2 (an antiapoptotic gene that acts downstream of CHOP)
in HIF-2a KD cells compared to shCtl cells (Figure 6E).
To further confirm the presence of ER stress, we performed
electron microscopy onHIF-2a KD CD34+ cells after they under-
went 6 days in liquid culture. Electron microscopy identifies fea-
tures of ER stress, shown by ER dilatation in the HIF-2a KD cells
compared to control cells (Figure 6D, right panel).
Considering the increase in both ROS production and ER
stress levels in HIF-2a KD cells, we wondered whether the in-
crease in ROS could trigger the activation of the UPR pathway,
ultimately leading to a decrease in the survival of the HSPCs
and therefore a decrease in engraftment in vivo. To answer this
question, we use GFP+ hCD45+ cells obtained from the BM of
transplantedmice (6 weeks posttransplant) and pretreated these
cells ex vivo with N-Acetyl-L-cysteine (NAC) or 4-Hydroxy-
TEMPO (TEMPOL), two potent antioxidants, for 24 hr, followed
by an additional treatment with TM for 24 hr (Figure 6F). We
measured the level of apoptosis using Annexin V/DAPI staining
before and after TM treatment. We observed that shHIF2a trans-
duced cells were more susceptible to apoptosis under TM treat-
ment compared to shCtl cells (Figure 6G). Furthermore, we were
able to rescue the apoptosis caused by TM by pretreating the
cells with either NAC or TEMPOL, after which significantly fewerCellapoptotic cells were observed (Figure 6H). To further confirm
the activation of the UPR pathway through the loss of control of
ROS production, we attempted to rescue the engraftment defect
observed inHIF-2a-silenced cells by treatingmice engraftedwith
shCtl- or shHIF2a-transduced cells with either NAC or TEMPOL
every other day for 6 weeks. As shown in Figure 6I, treatment
with TEMPOL, and to a lesser extent, NAC, was successful at
rescuing the engraftment defect caused by HIF-2a silencing.
From this, our data suggest a pathway by which HIF-2a
protects human HSPCs from ROS-induced ER stress and UPR
pathway activation.
HIF-2a KD Impedes the Growth of Human Primary Acute
Myeloid Leukemia
In solid tumors, the expression of HIF-2a has been associated
with poor prognosis (Qing and Simon, 2009). We therefore
decided to investigate the effect of the KD of HIF-2a on human
primary acute myeloid leukemia (AML). First, we compared the
level of expression of HIF-2a between CD34+ cells from normal
adult BM and 35 primary AML samples (33 samples at diagnosis
and 2 samples at both diagnosis and relapse). We observed a
large variability inHIF-2a levels in the AML samples tested,which
could be related to AML subtypes and genomic abnormalities.
Nevertheless, mean expression levels in AML were not signifi-
cantly different as compared to normal BM (Figure 7A). We
went on to evaluate the effect of HIF-2a KD on six AML samples
(Patient 3 being tested at diagnosis and relapse) in ex vivo long-
term culture. We saw a significant decrease in the percentage of
GFP+ cells over 3 weeks compared to shCtl in all samples tested
(p < 0.007) (Figure 7B).We confirmed thatHIF-2amRNAwas effi-
ciently silenced (75%) in the HIF-2a KD AML samples compared
to that in controls after 3 weeks in ex vivo cultures (Figure S5A).
Next, we went on to test the effect of this silencing in vivo in six
AML patient samples (Patient 3 being tested at diagnostic and
relapse). We observed an overall significant reduction (p <
0.001) in the engraftment of shHIF2a transduced cells, and in
two cases, a complete abolition of the engraftment of the leuke-
mia (Figure 7C). Of note, for Patient 3, we observed a more
potent inhibition of the engraftment from the relapse sample,
suggesting no acquisition of resistancemechanisms. To demon-
strate that this effect on engraftment involves the UPR pathway,
we treated AML cells ex vivo with TM and observed an increase
in apoptosis in shHIF2a transduced cells compared to shCtl (Fig-
ure S5B). This suggests that HIF-2a KD cells were more suscep-
tible to apoptosis as a result of ER stress. We also examined the
expression levels of HSPA5, CHOP, and GADD34 on these AML
patient samples and observed a clear upregulation of these
target genes under ER stress (Figure 7D).
Finally, to investigate if ROS was triggering apoptosis through
the UPR pathway, we pretreated the AML cells ex vivo with NAC
for 24 hr, followed this with an additional treatment with TM for
24 hr, and measured the level of apoptosis after treatment
(Figure 7E). Similar to what we observed in HSPCs, we were
able to rescue the apoptosis caused by TM by pretreating the
cells with NAC, as significantly fewer apoptotic cells were
observed (Figure 7F).
These data further indicate that HIF-2a is not only important for
the maintenance of human normal HSPCs, but is also active in
primary AML cells.Stem Cell 13, 549–563, November 7, 2013 ª2013 Elsevier Inc. 557
(legend on next page)
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HSPCs reside in hypoxic niches in the BM where low oxygen
levels play a key role in their maintenance. In the current report,
we investigated the role of HIF transcription factors in human
HSPCs. By knocking down HIF-1a and HIF-2a, we report that
HIF-2a, and to a lesser extend HIF-1a, plays a major role in the
regulation and maintenance of human HSPCs.
In vitro assays show that HIF-1a and HIF-2a are not required
for the production of human progenitors engaged in the myeloid
lineage since both HIF-1a- and HIF-2a-deficient myeloid cells
were able to form colonies (Figure 2A). This is in agreement
with the observations made in the Hif-1a-deficient mouse
models, whereHif-1a-deficient cells are still competent at gener-
ating CFU-Cs in vitro and CFU-Ss (12 days) after transplantation
(Takubo et al., 2010). Likewise, Hif-2a KO mouse BM cells pro-
duce normal CFU-Ss (8 days) (Scortegagna et al., 2003b).
In short-term repopulating assays (6weeksposttransplant), we
saw a significant decrease in hCD45+GFP+ cells engrafted in the
shHIF1a group and an even sharper drop in the shHIF2a group
(Figures 2D and 3B). This decrease was not due to a defect in
homing (Figure 2E). Based on the facts that at 1 week posttrans-
plant no difference in engraftment between control and shHIF2a
cells could be detected, and that our intravital imaging does not
show any difference in positioning 4 days posttransplant, we
ruled out a possible effect on the ‘‘niche anchorage’’ of at least
the shHIF2a cells in their microenvironment. Looking at long-
termengraftment, therewas aclear difference between the effect
of HIF1a and HIF2a KD, where no further reduction of human
engraftment was seen after 12 weeks in the shHIF1a group.
This was further confirmed by the percentage of CD34+CD38
present in the mice 24 weeks posttransplant, which was un-
changed in shHIF1a as compared to the control group (Figure 3F)
and the nonsignificant reduction in the engraftment after second-
ary transplantation (Figure 3G). Contrary to the conditionalHif-1a
KOmousemodel,where theonly significant defectwasobserved
in long-term repopulating capacity after serial transplantation,we
established that the downregulation of HIF-1a in human HSPCsFigure 6. Increase in ROS in HIF-2a KD Induces ER Stress, Triggering
(A) Schematic overview of the UPR pathway.
(B) RT-QPCR of HSPA5, CHOP, and GADD34 expression in CD34+ cells transduc
expressed in comparison to the level of shCtl.
(C) Left panel, same as (B) but cells were treated for 24 hr with TM prior tomRNA ex
for 6 days and received 24 hr of TM treatment before apoptosis was assessed. Dat
are shown as the mean ± SEM. *p < 0.05.
(D) Left panel, eIF2a, p-eIF2a, and B-ACTIN protein expression in CD34+ cells 8 da
day 4 based onGFP+, and cultured for another 4 days. Six hours before protein ex
KD CD34+ after 6 days in short-term liquid culture. Electron microscopy identifies
compared to control cells.
(E) RT-QPCR for HSPA5, CHOP, GADD34, and BCL-2 expression in CD45+GFP
posttransplantation. Gene expression was normalized to B-ACTIN and then to th
(F) Schematic representation of the experiment. Six weeks after transplantation,
24 hr in the presence or absence of NAC or TEMPOL before mice were treated wi
treatment. (shCtl, n = 5; shHIF-2a, n = 11.)
(G) Data represents the percentage of AnnexinV+ cells in the DAPI population.
(H) TM-induced apoptosis was rescued in presence of NAC (left panel) or TEMP
(I) Mice were transplanted with CD34+ cells transduced with either shCtl or shHIF2
percentage of GFP+ cells in the human engraftment normalized to 100%GFP at d
TEMPOL, n = 5; shHIF2a-PBS, n = 4; shHIF2a-NAC, n = 5; shHIF2a-TEMPOL, n
See also Figure S4.
Celldoes not significantly affect the long-term self-renewing multili-
neage repopulating cells. However, it is possible that this is
due to the compensatory upregulation of HIF-2a observed in
shHIF1a-transduced cells (Figure S2C). This is also supported
by theobservation thatHES-1, a target geneofHIF-2a, is upregu-
lated in HIF-1a KD cells (Figure 1D).
It appears, however, that HIF-2a has a major effect in the
maintenance of human HSPCs. Both short-term and long-term
repopulating cells were significantly decreased, with a particu-
larly sharp decrease in the HSPC compartment 24 weeks post-
transplant and a reduction in the secondary transplantation
capacity. We further show that this effect was due, at least in
part, to an increase in ROS production, which correlates with a
decrease in the expression of SOD2 and FXN, genes involved
in the cellular response to oxidative stress and in the mainte-
nance of mitochondrial homeostasis. High levels of oxidative
stress and increased levels of ROS have been previously
reported in Hif-2a/ mice (Scortegagna et al., 2003a) and in
Meis1/ HSCs, known to downregulate Hif-2a (Kocabas
et al., 2012; Scortegagna et al., 2003a). HIF-2a has also been
shown to regulate the expression of both Fxn and Sod2 in mouse
liver, where deletion of these genes results in mitochondrial dis-
ease (Oktay et al., 2007; Scortegagna et al., 2003a).
We show that in the BM, HSPCs silenced for HIF-2a have an
increase in ROS production, which increases ER stress and
activates the UPR pathway, the machinery that mediates the
regulation of ER stress. Indeed, we could detect the upregulation
of two downstream effectors, CHOP and GADD34 of the PERK
signal transducer pathway, as well as upregulation of GRP94
and HSPA5. The UPR is a survival response to reduce the accu-
mulation of unfolded proteins and to restore ER function. This
adaptive response of the cells is characterized by a decrease
in proliferation and protein synthesis. When ER stress cannot
be mitigated and homeostasis cannot be reestablished, pro-
longed activation of the UPR pathway (here under continuous
HIF-2a KD) results in the activation of cell death (review in Tabas
and Ron, 2011; Rutkowski and Hegde, 2010; Walter and Ron,
2011). Our experiments show that HIF-2a KD HSPCs culturedApoptosis
ed with shCtl or shHIF2a. B-ACTIN was used as control (n = 3). The results are
traction. Right panel, transduced shCtl and shHIF2aCD34+ cells were cultured
a represent the percentage of Annexin V+ cells in the DAPI population. Results
ys after transduction. CD34+were transduced with shCtl or shHIF2a, sorted on
traction cells were treated with TM. Right panel, electronmicroscopy on HIF-2a
features of ER stress, showed by the dilatation of the ER in the HIF-2a KD cells
+ human cells. Transduced CD45+/GFP+ cells were sorted from mice 6 weeks
e shCtl (n = 4). Results are shown as the mean ± SEM. *p < 0.05.
mice were sacrificed and BM from shCtl and shHIF2a mice was incubated for
th BM TM for another 24 hr. Early apoptosis was assessed before and after TM
Results are shown as the mean ± SEM. *p < 0.05.
OL (right panel). Results are shown as the mean ± SEM. *p < 0.05.
a and treated for 6 weeks with PBS, NAC, or TEMPOL. Results are shown as a
ay 4 and then to PBS-treated mice. ShCtl-PBS, n = 5; ShCtl-NAC, n = 4; ShCtl-
= 6. Results are shown as mean ± SEM. *p < 0.05.
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Figure 7. HIF-2a KD Impairs the Proliferation of Human Primary AML Cells
(A) Expression levels of HIF-2a in AML cells compared to normal adult BM CD34+ cells. B-ACTIN was used as control (BM CD34+ cells, n = 2; AML samples,
n = 33). Results are shown as mean ± SEM.
(B) Cell growth of five AML samples transduced with shCtl or shHIF-2a and cocultured on MS5 cells for 3 weeks. Data represent the percentage of GFP+ cells in
hCD45-AML cells during the culture period. Results are shown as normalized to day 4 (100%GFP+). Blue and red lines represent themean of the five AML patient
samples transduced with shCtl or shHIF2a, respectively. Overall p < 0.007.
(C) AML cells were transduced with shCtl or shHIF-2a and then injected into mice. Human graft was determined 12 weeks posttransplantation. Percentage of
GFP+ cells in the human graft normalized to day 4 (100%GFP+) is presented. Results represent one or two independent experiments and each dot represents one
mouse. Results are shown as mean ± SEM. Overall p < 0.001.
(D) RT-QPCR ofHSPA5,CHOP, andGADD34 expression in CD45+/GFP+ AML cells transducedwith shCtl or shHIF2a and treated for 24 hr with TM prior tomRNA
extraction. B-ACTIN was used as control. n = 4 AML patient samples. Results are shown as mean ± SEM. *p < 0.05.
(E) Schematic representation of the experiment. Twoweeks after transduction, AML cells were incubated for 24 hr in the presence or absence of NAC and then for
24 hr with TM.
(F) Apoptosis was assessed on shCtl and shHIF2a transduced AML samples 24 hr before and after TM treatment. Data represents the percentage of AnnexinV+
cells in the DAPI population.
See also Figure S5.
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explained by an increase in apoptosis, suggesting that cells may
be in the adaptive phase of the UPR pathway where they try to
restore ER functioning. However, in vivo, HIF-2a KD impairs
long-term engraftment of HSPCs, suggesting a defect in cell sur-
vival probably due to high levels of ER stress. In agreement with
that, our data demonstrate that HIF-2a-silenced cells (both
in vitro and ex vivo) are more susceptible to apoptosis when
they are under high levels of stress (i.e., when cells are treated
with a potent ER stress inducer like TM). This suggests that
HSPCs in the BM may be exposed to different stressors that,
in conjunction with the increase in ROS production caused by
HIF-2a KD, increase ER stress and make the cells undergo
apoptosis through the UPR pathway. Based on the multifactorial
effect of HIF-2a, it is possible that other pathways not described
here are also involved.
We show that the increase in apoptosis after TM treatment was
rescued by pretreating the cells with an antioxidant agent, like
NAC or TEMPOL, both ex vivo and in vivo, demonstrating that
ROS is upstream of the ER stress and UPR pathway in HSPCs.
The same activation of the ER stress by ROS has been reported
before inepithelial cellswherecadmiumcausedERstressviagen-
eration of ROS and ultimately apoptosis (Yokouchi et al., 2008).
We further demonstrate that the role of HIF-2a is not limited to
the normal regulation of HSPCs and show that the KD of HIF-2a
is also able to impede primary AML cells both ex vivo and in vivo
by using the same UPR pathway. In glioblastoma, it has been
shown recently that HIF-2a and multiple HIF-regulated genes
are preferentially expressed in glioma stem cells (GSCs) in com-
parison to nonstem tumor cells and normal neural progenitors.
Targeting both HIF-a subunits in GSCs inhibits self-renewal, pro-
liferation, and survival in vitro and attenuates tumor-initiating
potential of GSCs in vivo (Li et al., 2009). In AML, Wang et al.
(2011) have reported that HIF-1a seems to be restricted to the
CD34+CD38 fraction enriched in leukemic stem cells (LSCs)
and not in non-LSCs. Importantly, using the HIF-inhibitor echino-
mycin, they showed an efficient eradication of serially transplant-
able human AML in xenogenic models by preferential elimination
of LSCs. Based on the data reported here, it is arguable that at
least part of the effect of echinomycin treatment might have
been through HIF-2a downregulation. Although further studies
are needed, it is tempting to speculate that LSCs in AML might
use enhanced expression of HIF-2a to protect them from oxida-
tive stress. Therefore HIF-2a inhibition could still be proposed as
a therapeutic target in the context of AML patients with
enhanced ER stress, which would make them more prone to
apoptosis. This could only work within a specific time window
if the effect of silencing HIF-2a is more pronounced in AML
LSCs than in normal HSCs, which will need to be further evalu-
ated using potential HIF inhibitors.
All together, our data demonstrate the important regulatory
role of HIF-2a in human hematopoiesis, in both normal and
malignant conditions.EXPERIMENTAL PROCEDURES
Generation of Lentiviral Vectors and Viral Particles
Twenty-one bp sense and antisense oligonucleotides were designed in the
30-coding region of the human HIF-1a and HIF-2a genes. HIF-1b siRNACellsequence was purchased from Thermo Scientific, UK (Figure S1). DNA frag-
ments (Eurogentec, Angers, France) were cloned in the pic20-plasmid behind
the polymerase III H1 promoter. H1-shRNA sequences were subcloned in the
lentivirus (pTripDU3Ef1a-EGFPMCSDU3) that contains the enhanced GFP
(eGFP) gene under the control of the EF1a promoter. An shRNA directed
against the dsRed fluorescent protein (RFP) was used as a control (shCtl).
Lentiviral supernatants were produced by transient CaCl2 transfection of
HEK293T cells. The viral titers measured on HEK293T cells by FACS (on
eGFP expression),were 0.5 3 109 to 2 3 109 infectious particles/ml.
Source of Primary Human HSPCs and AML
UCB samples were obtained from normal full-term deliveries after signed
informed consent. AML samples were obtained after informed consent at
St Bartholomew’s Hospital (London, UK). Both protocols were approved by
the East London Ethical Committee and in accordance with the Declaration
of Helsinki. AML samples were collected at diagnosis (n = 37) or relapse
(n = 1). Details of patient samples are listed in Table S1.
Please refer to Supplemental Experimental Procedures for the remaining
methodologies, materials, and reagents used with this manuscript.
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